PhaseBio Pharmaceuticals, Inc.
PHAS · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $76,728 | $97,629 | $167,986 | $16,393 |
| - Cash | $41,800 | $28,122 | $74,025 | $61,031 |
| + Debt | $7,845 | $12,128 | $14,704 | $7,500 |
| Enterprise Value | $42,773 | $81,635 | $108,665 | -$37,138 |
| Revenue | $11 | $320 | $2,361 | $668 |
| % Growth | -96.6% | -86.4% | 253.4% | – |
| Gross Profit | $11 | $0 | $2,361 | $668 |
| % Margin | 100% | 0.1% | 100% | 100% |
| EBITDA | $1,663 | -$96,612 | -$37,997 | -$19,817 |
| % Margin | 15,350.2% | -30,191.3% | -1,609.4% | -2,966.6% |
| Net Income | -$131 | -$98,565 | -$39,247 | -$23,846 |
| % Margin | -1,210.1% | -30,801.6% | -1,662.3% | -3,569.8% |
| EPS Diluted | -0.005 | -3.39 | -1.43 | -4.49 |
| % Growth | 99.9% | -137.1% | 68.2% | – |
| Operating Cash Flow | -$47,416 | -$59,957 | -$39,594 | -$17,053 |
| Capital Expenditures | -$2,679 | -$1,412 | -$960 | -$119 |
| Free Cash Flow | -$50,095 | -$61,369 | -$40,554 | -$17,172 |